|Videos|October 21, 2017

Incentivizing Pharma Companies to Develop Lifesaving Drugs

Author(s)Contagion&reg Editorial Staff

James S. Lewis, PharmD, FIDSA, shares different proposals shared in the health care community to incentivize pharmaceutical companies to develop needed drugs.

James S. Lewis, PharmD, FIDSA, Co-Director of Antibiotic Stewardship, Oregon Health and Science University, shares different proposals shared in the health care community to incentivize pharmaceutical companies to develop needed drugs. Dr. Lewis warns that although antibiotic stewardship efforts are helping to slow down resistance, they will not be able to stop it from happening. With bacteria continually gaining resistance to available drugs, newer agents are desperately needed. In addition, Dr. Lewis also explains why susceptibility testing should be developed in parallel to new drugs that are being tested and developed.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Related to this article

November 7th, 2026

Carbapenem-Sparing Therapy for ESBL Bacteremia: New Trials, Old Questions

New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.

November 6th, 2026

Recent Guideline Updates in the Management of Urinary Tract Infections

Recent urinary tract infection guideline updates from multiple international medical societies highlight evolving recommendations, including a major shift in classification, moving from anatomy- and risk factor–based definitions toward distinguishing localized from systemic infections.

November 2nd, 2026

Cefiderocol Activity Improves in Physiologic Media, Synergizes With LL-37

Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.

November 1st, 2026

Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics

In a national survey of 959 US adults, 27.9% said they had exaggerated or made up symptoms to obtain antibiotics, most often cold-like symptoms, with implications for outpatient stewardship.

October 30th, 2026

Thinking Outside the IV: Implementation of a COpAT Program for Patients With Bone and Joint Infections

An APP-driven complex outpatient antimicrobial therapy (COpAT) program for patients with bone and joint infections cut mean time to post-discharge follow-up from 20.1 to 9.7 days but did not significantly reduce 30-day readmissions or emergency department visits.

October 29th, 2026

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections

Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.

October 29th, 2026

A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia

IDSA and ESCMID released 7 consensus statements to assist in managing individuals with Staphylococcus aureus Bacteremia (SAB). This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline.